Linked Data API

Show Search Form

Search Results

1701861
registered interest false more like this
date less than 2024-04-17more like thismore than 2024-04-17
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Antimicrobials: Drug Resistance more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, when she plans to publish the next action plan for antimicrobial resistance. more like this
tabling member constituency Linlithgow and East Falkirk remove filter
tabling member printed
Martyn Day more like this
uin 22343 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-23more like thismore than 2024-04-23
answer text <p>In 2019, the Government published the first of four five-year national action plans (NAP), aimed at tackling antimicrobial resistance (AMR) within and beyond our own borders. This plan is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024" target="_blank">https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024</a></p><p>We are now in the process of developing the second five-year NAP, which will run from 2024 to 2029. It will be designed to ensure progress is maintained towards delivering our 20-year vision on AMR, in which resistance is effectively contained and controlled by 2040. Further information on the 20-year vision is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance" target="_blank">https://www.gov.uk/government/publications/uk-20-year-vision-for-antimicrobial-resistance</a></p><p>The 2024 to 2029 AMR NAP is being co-developed across the Government, its agencies, and the administrations in Scotland, Wales, and Northern Ireland, with support from a wide range of external stakeholders, and informed by the responses to the Call for Evidence. The NAP is expected to be published in 2024.</p><p>The 2024 to 2029 AMR NAP will build on the achievements of the 2019 to 2024 NAP, whilst recognising where there is more to do, and will be aligned with global plans and frameworks for action.</p>
answering member constituency Lewes more like this
answering member printed Maria Caulfield more like this
question first answered
less than 2024-04-23T12:31:44.14Zmore like thismore than 2024-04-23T12:31:44.14Z
answering member
4492
label Biography information for Maria Caulfield more like this
tabling member
4488
label Biography information for Martyn Day more like this
1701128
registered interest false more like this
date less than 2024-04-15more like thismore than 2024-04-15
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Antibiotics: Drug Resistance more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, with reference to the Answer of 14 March 2022 to Question 133232 on Antibiotics: Drug Resistance and to the policy paper entitled UK five-year action plan for antimicrobial resistance: 2019 to 2024, published on 24 January 2019, what recent progress her Department has made on halving healthcare-associated Gram-negative blood stream infections. more like this
tabling member constituency Linlithgow and East Falkirk remove filter
tabling member printed
Martyn Day more like this
uin 21728 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-04-23more like thismore than 2024-04-23
answer text <p>As described in the answer of 14 March 2022 to Question 133232, progress towards the target of halving healthcare-associated Gram-negative bloodstream infections (GNBSI) has proved very challenging, in part due to the diverse nature of the underlying causes of these infections. Data on the incidence of these infections in England is published quarterly by the UK Health Security Agency, and is available at the following link:</p><p><br> <a href="https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data" target="_blank">https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data</a></p><p><br> Incidence of the three main healthcare-associated GNBSI organisms, E. coli, klebsiella pneumoniae, and pseudomonas aeruginosa, has fluctuated between 2019 and 2024, including a sharp decline in the incidence of E. coli seen during the COVID-19 pandemic. However, overall, the total incidence of healthcare associated GNBSI remains significantly above the target.</p><p>We are currently developing the 2024 to 2029 antimicrobial resistance national action plan. We anticipate that in the delivery of this plan, we will continue to focus on GNBSI, building on lessons learnt over the past five years.</p>
answering member constituency Lewes more like this
answering member printed Maria Caulfield more like this
question first answered
less than 2024-04-23T15:47:27.15Zmore like thismore than 2024-04-23T15:47:27.15Z
answering member
4492
label Biography information for Maria Caulfield more like this
tabling member
4488
label Biography information for Martyn Day more like this
1695234
registered interest false more like this
date less than 2024-03-12more like thismore than 2024-03-12
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Medical Equipment more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to increase uptake in the use of monitoring technologies by patients with diabetes. more like this
tabling member constituency Linlithgow and East Falkirk remove filter
tabling member printed
Martyn Day more like this
uin 18214 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-03-20more like thismore than 2024-03-20
answer text <p>The National Institute for Health and Care Excellence (NICE) has recently issued clinical guidelines in relation to the management of insulin dependent diabetes, covering patients living with type 1 and insulin dependent type 2 diabetes. This includes devices to support blood glucose monitoring. These recommendations are now being implemented by integrated care boards (ICBs).</p><p> </p><p>On 19 December 2023, NICE published its final recommendation on the hybrid closed loop system for people with type 1 diabetes. NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be first to be offered a hybrid closed loop system as part of a 5-year roll-out plan. NHS England has set out priorities for access, to help reduce healthcare inequalities through their implementation plan.</p><p> </p><p>Responsibility for the delivery of services and the implementation of NICE recommendations rests with the appropriate National Health Service commissioner. As diabetes care is commissioned by local ICBs, they are responsible for developing commissioning policies. ICBs must pay due regard to NICE guidance, however local decision making applies in terms of deciding whether to utilise their funding to implement the recommendation or not.</p>
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-03-20T17:11:23.963Zmore like thismore than 2024-03-20T17:11:23.963Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4488
label Biography information for Martyn Day more like this
1694161
registered interest false more like this
date less than 2024-03-06more like thisremove minimum value filter
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes: Medical Equipment more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 February 2024 to Question 15459 on Diabetes: Medical Equipment, what the evidential basis is for growth in the prescribing of diabetes technology for people living with type 2 diabetes. more like this
tabling member constituency Linlithgow and East Falkirk remove filter
tabling member printed
Martyn Day more like this
uin 17412 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2024-03-13more like thismore than 2024-03-13
answer text <p>The National Institute for Care and Excellence (NICE) published a recommendation in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections and a condition or disability that means they cannot use capillary blood glucose monitoring, should be offered Continuous Glucose Monitoring (CGM) technology, either real time or intermittent, to support self-monitoring.</p><p> </p><p>The NICE also recommended in March 2023 that adults with insulin-treated type 2 diabetes having their blood glucose monitored by a care worker or healthcare professional, are offered CGM. The rationale is that CGM can help to improve glycaemic control in adults with type 2 diabetes who use insulin.</p> more like this
answering member constituency Pendle more like this
answering member printed Andrew Stephenson more like this
question first answered
less than 2024-03-13T16:04:37.597Zmore like thismore than 2024-03-13T16:04:37.597Z
answering member
4044
label Biography information for Andrew Stephenson more like this
tabling member
4488
label Biography information for Martyn Day more like this